Hemostemix Clinical Trials

Every clinical trial we run aims to offer equitable trial access and an enhanced experience for both patients and physicians.

This site aims to help you make an informed decision as to whether participating in a clinical trial is the right thing for you or a loved one.

 

 

Explore our clinical trials

Are You thinking of joining a Clinical Trial?

Hemostemix Clinical Trials is a resource that addresses questions and concerns about clinical trials. This website also provides comprehensive information about certain medical conditions – their causes, symptoms and treatment options.

 

 

Vascular Dementia

Cognitive Decline Following A Stroke or Other Impairment of Blood Flow to the Brain.

Angina

A type of chest pain or discomfort caused by reduced blood flow to the heart muscle.

Peripheral Neuropathic Pain

Pain caused by a lesion or a disease of the peripheral somatosensory nervous system.

Publications

We share the results of our clinical trials in peer-reviewed journals and at professional scientific meetings

Our commitment to publication of results
We submit manuscripts for publication in peer-reviewed scientific and medical journals, with publication in the journals subject to the peer-review process at the discretion of the journal editors.

For all Hemostemix sponsored clinical trials (and all other interventional trials of medical significance) a manuscript will be submitted to peer-reviewed scientific and medical journals for publication. 

We also disclose clinical trial results by submitting abstracts and presenting posters and oral presentations at professional scientific meetings.

See Results of Completed Trials
Alt black stem image

 

These studies will be investigational and the therapies under evaluation have not been approved for general use.
Submitting this form expresses interest only — it does not enroll you in a study, guarantee eligibility, or promise access to treatment. Final eligibility will be determined by the study protocol and an IRB-approved informed consent process.
About Hemostemix
Hemostemix (TSXV:HEM OTCQB:HMTXF FSE:2VFO) is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed and patented ACP-01 - an autologous (patient's own) blood-based stem cell therapy. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer reviewed publications.